IP Library Granted Patent US 9,278,987
Granted Patent B2
US 9,278,987 · App. 14/358,992 · Granted Mar 8, 2016

Functionally-modified oligonucleotides and subunits thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,278,987
App. No.
14/358,992
Granted
Mar 8, 2016
Kind
B2
Abstract

Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Claims (240)

1. A compound having the structure of Formula (I):

or a salt or isomer thereof,

wherein:

n is an integer from 1 to 50;

G 5 is halogen, OH, alkoxy, OSO 2 (alkyl), OSO 2 (aryl), or

each B is an independently selected base pair moiety;

each Y is independently O or NR 10 ; optionally, R 10 and X8e are bonded together form a ring;

each W is independently S or O;

Z 5 is -(L 11 )-(R 15 ),-(L 11 )-(L 15 )-(R 16 ), or -(L 11 )-(L 12 )-(R 17 );

L 11 is selected from:

wherein L 13 is selected from:

L 12 is a linker cleaveable under biological conditions selected from:

a) —(C 1 -C 10 alkylene)-OC(O)O—CH 2 O—;

b) —C(O)—(C 1 -C 10 alkylene)-OC(O)O—CH 2 O—;

c) —C(O)—(CH═CH)—C(O)O—CH 2 O—;

d) —(C 1 -C 10 alkylene)-S—S—CH 2 CH 2 O—; or

e) —C(O)—(C 1 -C 10 alkylene)-S—S—CH 2 CH 2 O—;

L 15 is divalent radical selected from C 1 -C 30 alkylene, C 3 -C 8 cycloalkylene, C 6 -C 30 arylene, -(C 6 -C 30 arylene)-(C 1 -C 30 alkylene)-, -(C 1 -C 30 alkylene)-C(═O)—, —(C 2 -C 30 alkoxy) -C(═O)—, -(3-18 membered heteroalkylene)-C(═O)—, -(C 3 -C 8 cycloalkylene)-C(═O)—, —(C 3 -C 8 cycloalkylene)-(C 1 -C 30 alkylene)-C(═O)—, —(C 1 -C 30 alkylene) (C 3 -C 8 cycloalkylene)-C(═O)—, —(C 6 -C 30 arylene)-C(═O)—, —(C 6 -C 30 arylene)-(C 1 -C 30 alkylene)-C(═O)—, —(C 1 -C 30 alkylene)-(C 6 -C 30 arylene)-C(═O)—, —(C 1 -C 30 alkylene)-O—C(═O)—, —(C 3 -C 8 cycloalkylene)-O—C(═O)—, —(C 7 - C 30 arylene)-O—C(═O)—, —(C 6 -C 30 arylene)-(C 1 -C 30 alkylene) -O—C(═O)—, —(C 6 -C 30 arylene)-(C 1 -C 30 alkylene)-O—C(═O)—, —C(═O)OR 21 , or —P(═O)(R 22 ) 2 ;

R 12 is an electron pair, with the provision that if R 13 is C 1 -C 30 alkyl, then R′ 2 is an electron pair, an N-oxide, or C 1 -C 6 alkyl;

each R 10 and R 13 is independently selected from hydrogen, a cell-penetrating peptide, a natural or non-natural amino acid, guanidinyl, amidinyl, heterocyclyl, C 1 -C 30 alkyl, C 3 -C 8 cycloalkyl; C 6 -C 30 aryl, C 7 -C 30 aralkyl, C 1 -C 30 alkylcarbonyl, C 3 -C 8 cycloalkylcarbonyl, C 3 -C 8 cycloalkylalkylcarbonyl, C 6 -C 30 arylcarbonyl, C 7 -C 30 aralkylcarbonyl, C 1 -C 30 alkyloxycarbonyl, C 3 -C 8 cycloalkyloxycarbonyl, C 7 -C 30 aryloxycarbonyl, C 8 -C 30 aralkyloxycarbonyl, —C(═O)OR 21 , —C(═O)NHR 21 , or —P(═O)(R 22 ) 2 ;

R 15 is independently selected from a cell-penetrating peptide, a natural or non-natural amino acid, guanidinyl, amidinyl, heterocyclyl, C,-C 30 alkyl, C 3 -C 8 cycloalkyl; C 6 -C 30 aryl, C 7 -C 30 aralkyl, C 1 -C 30 alkylcarbonyl, C 3 -C 8 cycloalkylcarbonyl, C 3 -C 8 cycloalkylalkylcarbonyl, C 6 -C 30 arylcarbonyl, C 7 -C 30 aralkylcarbonyl, C 2 -C 30 alkyloxycarbonyl, C 3 -C 8 cycloalkyloxycarbonyl, C 7 -C 30 aryloxycarbonyl, C 8 -C 30 aralkyloxycarbonyl, 3-18 membered alkoxyalkylcarbonyl, —SO 2 R 21 , —C(═O)OR 21 , —P(═O)(OH) 2 or —P(═O)(R 22 ) 2 ;

R 16 is a solid support matrix suitable for solid phase synthesis of oligonucleotides;

R 17 is a drug, protein or toxin;

each R 21 is independently C 1 -C 30 alkyl, or a 3-18 membered alkoxyalkyl group;

each R 22 is independently an C 6 -C 12 aryloxy;

each R 23 is independently H or C 1 -C 6 alkyl; or optionally two R 23 groups join to form a 3- to 8-membered ring;

R 24 is a C 1 -C 6 alkylene;

Q is independently selected from X1, X2, X3, X4, X5, X6, X7, or X8;

each X is independently selected from X1, X2, X3, X4, X5, X6, X7, or X8 with the provision that at least one X is not X1;

wherein

X1 is N(CH 3 ) 2 ;

X2 is selected from:

a) —O-alkylene-CO 2 H;

b) —O-alkylene-CHN 4 ;

c) —N(R 1 )-alkylene-CO 2 H;

d) —N(R 1 )-alkylene-CHN 4 ;

e) -L1-CO-alkylene-CO 2 H;

f) -L1-CO-alkylene-CHN 4 ;

g) -L1-CO-alkenylene-CO 2 H;

h) -L1-CO-alkenylene-CHN 4 ;

i) -L1-CO-arylene-CO 2 H;

j) -L1-CO-arylene-CHN 4 ;

k) -L1-CONH-alkylene-CO 2 H;

l) -L1-CONH-alkylene-CHN 4 ;

m) -L1-CONH-arylene-CO 2 H;

n) -L1-CONH-arylene-CHN 4 ;

o) -L1-SO 2 -alkylene-CO 2 H;

p) -L1-SO 2 -alkylene-CHN 4 ;

q) -L1-SO 2 -arylene-CO 2 H;

r) -L1-SO 2 -arylene-CHN 4 ;

s) -L1-alkylene-CO 2 H;

t) -L1-alkylene-CHN 4 ;

u) -L1-arylene-CO 2 H;

v) -L1-arylene-CHN 4 ; and

w) a protected form of any of the above X2 groups;

X3 is selected from:

a) -L1-alkyl;

b) -L1-heterocyclyl;

c) —O-alkylene-CNH—NH 2 ;

d) —N(R 1 )-alkylene-CNH—NH 2 ;

e) -L1-CNH—NH 2 ;

f) -L1-alkylene-CNH—NH 2 ;

g) -L1-arylene-CNH—NH 2 ;

h) -L1-CO-alkylene-CNH—NH 2 ;

i) -L1-CO-alkenylene-CNH—NH 2 ;

j) -L1-CO-arylene-CNH—NH 2 ;

k) -L1-CONH-alkylene-CNH—NH 2 ;

l) -L1-CONH-arylene-CNH—NH 2 ;

m) -L1-SO 2 -alkylene-CNH—NH 2 ;

n) -L1-SO 2 -arylene-CNH—NH 2 ;

o) —O-alkylene-N(R 1 ) 2 ;

p) —N(R 1 )-alkylene-N(R 1 ) 2 ;

q) -L1-N(R 1 ) 2 ;

r) -L1-alkylene-N(R 1 ) 2 ;

s) -L1-arylene-N(R 1 ) 2 ;

t) -L1-CO-alkylene-N(R 1 ) 2 ;

u) -L1-CO-alkenylene-N(R 1 ) 2 ;

v) -L1-CO-arylene-N(R 1 ) 2 ;

w) -L1-CONH-alkylene-N(R 1 ) 2 ;

x) -L1-CONH-arylene-N(R 1 ) 2 ;

y) -L1-SO 2 -alkylene-N(R 1 ) 2 ;

z) —O-alkylene-N(R 2 ) 3 ;

aa) —N(R 1 )-alkylene-N(R 2 ) 3 ;

bb) -L1-N(R 2 ) 3 ;

cc) -L1-alkylene-N(R 2 ) 3 ;

dd) -L1-arylene-N(R 2 ) 3 ;

ee) -L1-CO-alkylene-N(R 2 ) 3 ;

ff) -L1-CO-alkenylene-N(R 2 ) 3 ;

gg) -L1-CO-arylene-N(R 2 ) 3 ;

hh) -L1-CONH-alkylene-N(R 2 ) 3 ;

ii) -L1-CONH-arylene-N(R 2 ) 3 ;

jj) -L1-SO 2 -alkylene-N(R 2 ) 3 ;

kk) —O-alkylene-heterocyclyl;

ll) —N(R 1 )-alkylene-heterocyclyl;

mm) -L1-alkylene-heterocyclyl;

nn) -L1-arylene-heterocyclyl;

oo) -L1-CO-alkylene-heterocyclyl;

pp) -L1-CO-alkenylene-heterocyclyl;

qq) -L1-CO-arylene-heterocyclyl;

rr) -L1-CONH-alkylene-heterocyclyl;

ss) -L1-CONH-arylene-heterocyclyl;

tt) -L1-SO 2 -alkylene-heterocyclyl;

uu) —O-alkylene-N(O)(R 2 ) 2 ;

vv) —N(R 1 )-alkylene-N(O)(R 2 ) 2 ;

ww) -L1-N(O)(R 2 ) 2 ;

xx) -L1-alkylene-N(O)(R 2 ) 23 ;

yy) -L1-arylene-N(O)(R 2 ) 2 ;

zz) -L1-CO-alkylene-N(O)(R 2 ) 2 ;

aaa) -L1-CO-alkenylene-N(O)(R 2 ) 23 ;

bbb) -L1-CO-arylene-N(O)(R 2 ) 2 ;

ccc) -L1-CONH-alkylene-N(O)(R 2 ) 2 ;

ddd) -L1-CONH-arylene-N(O)(R 2 ) 2 ;

eee) -L1-SO 2 -alkylene-N(O)(R 2 ) 2 ;

fff) —O-alkylene-NH—CNH—NH 2 ;

ggg) —N(R 1 )-alkylene-NH—CNH—NH 2 ;

hhh) -L1-NH—CNH—NH 2 ;

iii) -L1-alkylene-NH—CNH—NH 2 ;

jjj) -L1-arylene-NH—CNH—NH 2 ;

kkk) -L1-CO-alkylene-NH—CNH—NH 2 ;

lll) -L1-CO-alkenylene-NH—CNH—NH 2 ;

mmm) -L1-CO-arylene-NH—CNH—NH 2 ;

nnn) -L1-CONH-alkylene-NH—CNH—NH 2 ;

ooo) -L1-CONH-arylene-NH—CNH—NH 2 ;

ppp) -L1-SO 2 -alkylene-NH—CNH—NH 2 ;

qqq) -L1-SO 2 -arylene-NH—CNH—NH 2 ; and

rrr) a protected form of any of the above X3 groups;

with the provision that if X1 is present as N(CH 3 ) 2 , and X7 is present as piperidinyl, then X3 is not:

X4 is selected from:

a) —O-alkylene-aryl;

b) —N(R 1 )-aryl;

c) —N(R 1 )-alkylene-aryl;

d) -L1-CO-alkylene-aryl;

e) -L1-CO-alkenylene-aryl;

f) -L1-CO-arylene-aryl;

g) -L1-CONH-alkylene-aryl;

h) -L1-CONH-arylene-aryl;

i) -L1-SO 2 -alkylene-aryl;

j) -L1-SO 2 -arylene-aryl;

k) -L1-alkylene-aryl;

l) -L1-arylene-aryl;

m) —N(R 1 )-alkylene-N(R 1 )-aryl;

n) —N(R 1 )-alkylene-N(R 1 )CO-aryl;

o) —N(R 1 )-alkylene-N(R 1 )SO 2 -aryl;

p) —N(R 1 )-alkylene-N(R 1 )CH 2 -aryl;

q) -L1-aryl;

r) -L1-CO-aryl;

s) -L1-SO 2 -aryl;

t) -L1-alkylene-P(aryl) 3 ;

u) -L1-CO-alkylene-P(aryl) 3 ;

v) -L1-SO 2 -alkylene-P(aryl) 3 ; and

w) a protected form of any of the above X4 groups;

X5 is selected from:

a) —O-alkylene-heteroaryl;

b) —N(R 1 )-alkylene-heteroaryl;

c) -L1-CO-alkylene-heteroaryl;

d) -L1-CO-alkenylene-heteroaryl;

e) -L1-CO-arylene-heteroaryl;

f) -L1-CONH-alkylene-heteroaryl;

g) -L1-CONH-arylene-heteroaryl;

h) -L1-SO 2 -alkylene-heteroaryl;

i) -L1-SO 2 -arylene-heteroaryl;

j) -L1-alkylene-heteroaryl;

k) -L1-arylene-heteroaryl;

l) —N(R 1 )-alkylene-N(R 1 )-hereroaryl;

m) —N(R 1 )-alkylene-N(R 1 )CO-hereroaryl;

n) —N(R 1 )-alkylene-N(R 1 )SO 2 -hereroaryl;

o) —N(R 1 )-alkylene-N(R 1 )CH 2 -hereroaryl;

p) -L1-heteroaryl; and

q) a protected form of any of the above X5 groups;

X6 is selected from:

a) —O-alkylene-(OCH 2 CH 2 ) m OH;

b) —O-alkylene-(OCH 2 CH 2 ) m OCH 3 ;

c) —N(R 1 )-alkylene-(OCH 2 CH 2 ) m OH;

d) —N(R 1 )-alkylene-(OCH 2 CH 2 ) m OCH 3 ;

e) —N(R 1 )-arylene-(OCH 2 CH 2 ) m OH;

f) —N(R 1 )-arylene-(OCH 2 CH 2 ) m OCH 3 ;

g) -L1-alkylene-(OCH 2 CH 2 ) m OH;

h) -L1-CO-alkylene-(OCH 2 CH 2 ) m OH;

i) -L1-CO-alkylene-(OCH 2 CH 2 ) m OCH 3 ;

j) -L1-SO 2 -alkylene-(OCH 2 CH 2 ) m OH;

k) -L1-SO 2 -alkylene-(OCH 2 CH 2 ) m OCH 3 ;

l) -L1-CO-arylene-(OCH 2 CH 2 ) m OH;

m) -L1-CO-arylene-(OCH 2 CH 2 ) m OCH 3 ;

n) -L1-SO 2 -arylene-(OCH 2 CH 2 ) m OH;

o) -L1-SO 2 -arylene-(OCH 2 CH 2 ) m OCH 3 ;

p) -L1-CO—(OCH 2 CH 2 ) m OH;

q) -L1-CO—(OCH 2 CH 2 ) m OCH 3 ;

r) —N(R 1 )-(dibenzo-18-crown-6);

s) an aza-crown ether; and

t) a protected form of any of the above X6 groups;

X7 is selected from:

a) -heterocyclyl;

b) —N(R 1 )(R 3 )

c) -L1-hydrogen;

d) -L1-alkyl;

e) -L1-CO-alkyl;

f) -L1-CONH-alkyl;

g) -L1-CON(alkyl)-alkyl;

h) -L1-SO 2 -alkyl; and

i) a protected form of any of the above X7 groups;

with the provision that if X1 is present as N(CH 3 ) 2 , and X3 is present as

then X7 is not piperidinyl;

X8 is selected from:

a) -L1-CA;

b) -L1-dCA;

c) -L1-COCH 2 (R 4 )

d) -L1-COCH(R 4 )NHCO 2 -alkyl;

e) —OR 5 , wherein R 5 and R 10 together form a ring;

f) a protected form of any of the above X8 groups;

each R 1 is independently hydrogen, alkyl, or a cell-penetrating peptide;

each R 2 is independently C 1 -C 12 alkyl or optionally when two R 2 are C 1 -C 12 alkyl, two R 2 are joined to form a heterocyclic ring;

each R 3 is independently C 2 -C 18 alkyl, alkenyl, or alkynyl;

each R 4 is independently hydrogen, alkyl, hydroxyalkyl, sulfhydrylalkyl, or arylalkyl;

each R 5 is independently C 1 -C 12 alkyl;

each R 6 is independently hydrogen or C 1 -C 12 alkyl;

L1 is selected from:

wherein

each Q 1 and Q 2 are each selected from a bond, —O— or —N(R 6 )—;

each E 1 is independently selected from optionally substituted aryl or optionally substituted heteroaryl;

each E 2 is independently an optionally substituted nitrogen containing heteroaryl;

each L 4 and L 5 are each independently a bond, optionally substituted C 1 -C 6 alkyl, or optionally substituted heteroalkyl; and

m, p, q, s, and t are each independently 1-4,

wherein if the X group proximal to the 3′ terminus is:

then at least one other X group is not X1, and

wherein the compound is not of the formula:

2. The compound of claim 1 , wherein G5 is of the formula:

3. The compound of claim 2 , wherein Z 5 is -(L 11 )-(R 15 ); each Y is independently O, NH, or NR 10 ; each W is O; each R 1 is independently hydrogen or alkyl; and each R 2 is independently C 1 -C 12 alkyl.

4. The compound of claim 2 , wherein each W is O and each Y is O.

5. The compound of claim 4 , wherein at least one X is selected from:

6. The compound of claim 4 , wherein at least one X is L1-heterocyclyl, and wherein L1 is selected from:

7. The compound of claim 4 , wherein at least one X is selected from:

8. The compound of claim 4 , wherein at least one X is selected from —N(R 1 )-alkylene—NH—H 2 , —N(R 1 )-alkylene-N(R 1 ) 2 , —N(R 1 )-alkylene-N(R 2 ) 3 , —N(R 1 )-alkylene-heterocyclyl, —N(R 1 )-alkylene-N(O)(R 2 ) 2 , or -N(R 1 )-alkylene-NH—CNH—NH 2 .

9. The compound of claim 4 , wherein at least one X is selected from -L1-heteroaryl, -L1-alkylene-heteroaryl, -L1-arylene-heteroaryl, -L1-CO-alkylene-heteroaryl, -L1 -CO-alkenylene-heteroaryl, -L1-CO-arylene-heteroaryl, -L1—CONH—-alkylene-heteroaryl, -L1 -CONH-arylene-heteroaryl, -L1 -SO 2 -alkylene-heteroaryl, or -L1-SO -2 arylene-heteroaryl.

10. The compound of claim 4 , wherein at least one X is -L1-CO-alkyl.

11. The compound of claim 4 , wherein at least one X is selected from -O-alkylene-aryl, -N(R1)-aryl, -N(R1)-alkylene-aryl, -N(R1)-alkylene-N(R1) -aryl, -N(R1)-alkylene-N(R1)CO-aryl, -N(R1)-alkylene-N(R1)SO2-aryl, and -N(R1)-alkylene-N(R1)CH2-aryl.

12. The compound of claim 4 , wherein at least one X is selected from -O-alkylene-heteroaryl, -N(R1)-alkylene-heteroaryl, -N(R1)-alkylene-N(R1)-heteroaryl, -N(R1)-alkylene-N(R1)CO-heteroaryl, -N(R1)-alkylene-N(R1)SO2-heteroaryl, and -N(R1)-alkylene-N(R1)CH2-heteroaryl.

13. The compound of claim 4 , wherein at least one X is X8.

14. The compound of claim 4 , wherein Z 5 is -(L 11 )-(R 15 ) wherein R 15 is selected from —C(═O)OCH 2 CH 2 OH, —(═O)OCH 2 CH 2 OCH 2 CH 2 OH, or —C(═O)OCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OH.

15. The compound of claim 14 , wherein Z 5 is of the formula:

16. The compound of claim 1 , wherein R 13 is an optionally substituted triphenylmethyl group.

Assignments (2)
SECURITY INTEREST Recorded May 7, 2025
From: SAREPTA THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 071218/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2014
From: HANSON, GUNNAR J.; WELLER, DWIGHT D.; CAI, BAO ZHONG; ZHOU, MING
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 032917/0925 →